The Risks of miRNA Therapeutics: In a Drug Target Perspective

This article was published in the following Dove Press journal:
Drug Design, Development and Therapy

Song Zhang^{1,2}
Zhujun Cheng³
Yanan Wang¹
Tianyu Han¹

¹Jiangxi Institute of Respiratory Disease, The First Affiliated Hospital of Nanchang University, Nanchang, 330006, People's Republic of China; ²College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, People's Republic of China; ³Department of Burn, The First Affiliated Hospital of Nanchang University, Nanchang, 330006, People's Republic of China

Abstract: RNAi therapeutics have been growing. Patisiran and givosiran, two siRNA-based drugs, were approved by the Food and Drug Administration in 2018 and 2019, respectively. However, there is rare news on the advance of miRNA drugs (another therapeutic similar to siRNA drug). Here we report the existing obstacles of miRNA therapeutics by analyses for resources available in a drug target perspective, despite being appreciated when it began. Only 10 obtainable miRNA drugs have been in clinical trials with none undergoing phase III, while over 60 siRNA drugs are in complete clinical trial progression including two approvals. We mechanically compared the two types of drug and found that their major distinction lay in the huge discrepancy of the target number of two RNA molecules, which was caused by different complementary ratios. One miRNA generally targets tens and even hundreds of genes. We named it “too many targets for miRNA effect” (TMTME). Further, two adverse events from the discontinuation of two miRNA therapeutics were exactly answered by TMTME. In summary, TMTME is inevitable because of the special complementary approach between miRNA and its target. It means that miRNA therapeutics would trigger a series of unknown and unpreventable consequences, which makes it a considerable alternative for application.

Keywords: RNAi, miRNA, siRNA, therapeutics

Introduction

In 1993, Lee et al discovered endogenous single-stranded approximately 22-nt lin-4 (a miRNA) could decrease the level of LIN-14 protein in *C. elegans*,¹ and since then, researchers have reported a series of miRNAs that could inhibit the expression of specific proteins. In 2001, Elbashir et al reported double-stranded 21-nucleotide (nt) siRNA could induce RNA interference (RNAi) in different mammalian cell lines,² and soon siRNAs were used as useful tools for gene silencing in biomedical research. Both types of RNA molecules could lead to inhibition of gene expression, but miRNA is complementary to the 3' untranslated region of mRNA¹ and siRNA is complementary to the coding region of mRNA.² However, two similar mechanistic RNA molecules were under different progression for biomedical applications. In 2006, Craig Mello and Andrew Fire were awarded the Nobel Prize in Physiology or Medicine for their contributions to RNAi, which, however, excluded work on miRNA. Until 2020, a number of treatments based on siRNA technology have undergone clinical trials, and two such products, patisiran³ and givosiran⁴, have been approved. But nearly 30 years later, miRNA did not benefit treatment of diseases even with none entering phase III clinical trials. In this article, we explore

Correspondence: Tianyu Han
Email hantianyu87@163.com

the delayed development of miRNA in a drug target perspective, and identify therapeutic risks of miRNA despite its great appreciation by many reports.^{5–9}

Comparison of miRNA Drugs and siRNA Drugs

To understand the latest and detailed progression of RNAi, we first obtained clinical trial information of miRNA drug and siRNA drug (including shRNA, a small RNA molecule executing the same function as siRNA) from ClinicalTrials.gov,¹⁰ Drugs@FDA database,¹¹ a series of literature,^{3,4,12,13} and a company report¹⁴ (Tables 1 and 2). The information presented in Table 2 originated from Weng's study¹³, and we updated the current phase status of the clinical trials for these drugs. In our statistics, it launched 10 miRNA drugs in clinical trial, with one phase I, four phase II and five terminated/suspended (Table 1 and Figure 1A). However, 57 siRNA drugs (targeting human proteins/genes) were ongoing or completed clinical trials, including 16 phase I, 16 phase II, eight phase III, 23 terminated/suspended therapeutics (Table 2 and Figure 1A). As shown (Figure 1B), no miRNA drugs were in phase III trials, while siRNA drugs seemed to be in a complete clinical trial system without missing any segments. Moreover, we found that miRNA drugs suffered 50% terminated/suspended therapeutics, while 35.38% terminated/suspended therapeutics appeared

in siRNA drugs (Figure 1B). Therefore, it may indicate there were potentially unclear obstacles for miRNA therapeutics.

Inherently, miRNA is endogenously produced and siRNA is exogenously designed. Designers can exactly endow siRNA giving them the purpose of gene silencing, while endogenous miRNA seemed more complicated because nobody assigned them specific tasks. We mechanically analyzed the differences between miRNA and siRNA in their complementary modes with the target sequences. As expected, Figure 2A showed a flexible complementary ratio of miRNA with target sequence (within the range 20–90%) and none with complete complementation, but all siRNAs had 100% complementary ratio. The less restricted complementary mode may lead to low specificity of target sequence. Next, we employed miRTarBase¹⁵ to obtain targets of miRNAs for ten miRNA drugs, and compared the number of targets in miRNA drug* (referring to all targets of miRNA including experiment-validated and high-throughput results in miRTarBase), miRNA drug (referring to targets of miRNA only including experiment-validated results) and siRNA drugs. Beyond our expectation, the targets of the miRNA drug ranged from 30 to 250 in number and almost all miRNA drug* were over 500 and even 1000, but the si0052NA drug generally targets 1–3 genes (Figure 2B). The majority of miRNA targets tens and hundreds of genes, and we named it “too many targets for miRNA effect” (TMTME).

Table 1 Clinical Information of miRNA Drugs

Drug Name	Target(s)/Employed miRNA(s)	Current Status	Condition(s)	Company
Lademirsen (SAR339375, RG-012)	miR-21	II	Alport syndrome	Genzyme
MRG-201 (Remlarsen)	miR-29	II	Keloid	miRagen Therapeutics, Inc.
RG-125 (AZD4076)	miR-103/107	II	Nonalcoholic fatty liver disease	AstraZeneca
MRG-106	miR-155	I	Lymphomas; leukemias	miRagen Therapeutics, Inc.
MRG-110	miR-92a	I	Skin excisional wound	miRagen Therapeutics, Inc.
MesomiR I	miR-16	Suspended	Malignant pleural mesothelioma; non-small-cell lung cancer	Asbestos Diseases Research Foundation
Miravirsen	miR-122	Suspended	Chronic hepatitis C	Santaris Pharma A/S
RG-101	miR-122	Discontinued	Chronic hepatitis C	Regulus Therapeutics Inc.
pSil-miR200c and PMIS miR200a	miR-200a/c	Discontinued	Tooth extraction status nos	University of Iowa
MRX34	miR-34a	Discontinued	Melanoma; primary liver cancer; hematologic malignancies	Mirna Therapeutics, Inc.

Table 2 Clinical Information of siRNA Drugs

Drug Name	Target(s)	Current Status	Indication(s)	Company
ONPATTRO (Patisiran, ALN-TTR02)	TTR	Approved	Transthyretin (TTR)-mediated amyloidosis	Alnylam Pharmaceuticals
Givlaari (Givosiran, ALN-ASI)	ALAS-1	Approved	Acute hepatic porphyrias	Alnylam Pharmaceuticals
Fitusiran (ALN-AT3sc, ALN-APC, SAR439774)	Thrombin	III	Hemophilia A, hemophilia B	Alnylam Pharmaceuticals
Vutrisiran (ALN-TTRsc02)	TTR	III	Transthyretin (TTR)-mediated amyloidosis	Alnylam Pharmaceuticals
Tivaisiran (SYL1001)	TRPV1	III	Ocular pain, dry eye	Sylentis, S.A.
Lumasiran (ALN-GO1)	HAO1	III	Primary hyperoxaluria type 1 (PH1)	Alnylam Pharmaceuticals
Inclisiran (ALN-PCSc)	PCSK9	III	Hypercholesterolemia	Alnylam Pharmaceuticals
Vigil vaccine (FANG, vigil, vigil EATC)	Furin	III	Breast cancer (III), ovarian cancer (II), colorectal cancer (I), Ewing's sarcoma (II), metastatic melanoma (II), metastatic non-small-cell lung cancer (II), solid tumors (I)	Gradalis, Inc.
QPI-1002 (ISNP)	p53	III	Delayed graft function (III), acute kidney injury (II)	Quark Pharmaceuticals
DCR-PHXC	LDHA	III	Primary hyperoxaluria	Dicerna Pharmaceuticals
ARO-HBV	HBV gene	II	Hepatitis B	Arrowhead Pharmaceuticals
PSCT19 (MiHA-loaded PD-L-silenced DC vaccination)	PD-L1/PD-L2	II	Hematological malignancies	Radboud University
Cemdisiran (ALN-CC5)	C5a Receptor	II	Paroxysmal nocturnal hemoglobinuria (PNH)	Alnylam Pharmaceuticals
STP705 (cotsiranib)	TGF- β 1 and COX-2	II	Hypertrophic scar (wound healing)	Sirnaomics
SYL040012 (bamosiran)	ADRB2	II	Open angle glaucoma, ocular hypertension	Sylentis, S.A.
Lentivirus vector CCR5 shRNA	CCR5	II	AIDS-related lymphoma	AIDS Malignancy Consortium
Cal-1 (LVsh5/C46, Cal-1 modified HSPC, Cal-1 modified CD4 + T lymphocytes)	CCR5	II	HIV/AIDS	Calimmune Inc.
PF-655 (PF-04523655)	RTP801	II	Diabetic macular edema (II), age-related macular degeneration (II)	Quark Pharmaceuticals

(Continued)

Table 2 (Continued).

Drug Name	Target(s)	Current Status	Indication(s)	Company
Atu027	PKN3	II	Metastatic pancreatic cancer (II), solid tumors (I), head and neck cancer (hold)	Silence Therapeutics GmbH
TKM-080301 (TKM-PLK1)	PLK1	II	Adrenal cortical carcinoma (II), hepatocellular carcinoma (II), neuroendocrine tumor (II), solid tumors (I)	Arbutus Biopharma Corporation
ND-L02-s0201	HSP47	II	Hepatic fibrosis	Bristol Myers Squibb, Nitro Denko Corporation
CEQ508	CTNINB1	II	Familial adenomatous polyposis	Marina Biotech
RXI-109 (sd-rxRNA)	CTGF	II	Scar (II), wet age-related macular degeneration (II), ophthalmology (I/II), retinal neovascularization (I/II)	Phio Pharmaceuticals Corp
BMT101	CTGF	II	Hypertrophic scar	Hugel
siG12D LODER	KRAS	II	Pancreatic ductal adenocarcinoma, pancreatic cancer	Silenseed Ltd
ALN-AAT02	AAT	II	Antitrypsin Deficiency Liver Disease	Alnylam Pharmaceuticals
DCR-HBVS	HBV	I	Hepatitis B	Dicerna Pharmaceuticals
Lentivirus vector rHIV7-sh1-TAR-CCR5RZ-transduced hematopoietic progenitor cells	HIV-1 tat/rev(sh1)-trans-actve response element (TAR), CCR5 ribozyme	I	Chronic lymphocytic leukemia (CLL) hepatitis C	City of Hope Medical Center
iPsiRNA (Proteasome siRNA and tumor antigen RNA-transfected DC)	LMP2, LMP7, MECL1	I	Metastatic melanoma, absence of CNS metastases	Scott Pruitt, Duke University
pbi-shRNA EWS/FLI1 type 1 LPX	EWS/FLI1	I	AIDS-related lymphoma	Gradalis, Inc.
SXL01	AR V7 variant	I	Metastatic castration-resistant prostate cancer (CRPC)	Institut Claudius Regaud
siRNA-EphA2-DOPC	EphA2	I	Advanced cancers	M.D. Anderson Cancer Center
ARO-ANG3	ANGPTL3	I	Dyslipidemia, hypercholesterolemia	Arrowhead Pharmaceuticals
NU-0129	BCL2L12	I	Glioma	Northwestern University
ARO-AAT	AAT	I	Alpha-1 antitrypsin deficiency	Arrowhead Pharmaceuticals

APN401 (siRNA-transfected PBMC)	Cbl-b/DC cancer vaccine	I	Solid tumors	Wake forest university health sciences
OLX10010	CTGF	I	Cicatrix, hypertrophic	Olix Pharmaceuticals
pbi-shRNA STMN1 LP	STMN1	I	Ewing's sarcoma	Gradalis, Inc.
AMG 890	Lp(a)	I	Cardiovascular disease	Amgen
ARO-APOC3	ApoC3	I	Hypertriglyceridemia, familial chylomicronemia	Arrowhead Pharmaceuticals
TD101	Keratin 6A N171K mutant	I	Pachyonychia congenita	Pachyonychia Congenita Project
Mesenchymal stromal cells-derived exosomes with KRAS G12D siRNA	KrasG12D mutation	I	Pancreatic cancer	M.D. Anderson Cancer Center
TKM-Ebola-Guinea (TKM-I 30,803)	VP35, Zaire Ebola L-polymerase	Suspended	West African, Ebola virus infection	Arbutus Biopharma Corporation
ARB-1467 (ARB-001467)	HBV genome	Suspended	Hepatitis B	Arbutus Biopharma Corporation
ALN-HBV	HBV gene	Suspended	Hepatitis B	Alnylam Pharmaceuticals
TKM-Ebola (TKM-Ebola Kikwit, TKM-100,201, TKM-100,802)	VP24, VP35, Zaire Ebola L-polymerase	Suspended	Ebola virus infection	Arbutus Biopharma Corporation
TT-034 (PF-05095808)	HCV gene	Suspended	Hepatitis c	Tacere Therapeutics
ALN-VSP02 (ASC-06)	VEGF, KSP	Suspended	Solid tumors	Alnylam Pharmaceuticals
Bevasiranib (Cand5)	VEGF	Suspended	Diabetic macularedema, macular degeneration, age-related macular degeneration	OPKO Health, Inc.
AGN211745 (AGN-745, Sima-027)	VEGFR1	Suspended	Age-related macular degeneration, choroidal neovascularization	Allergan, Inc.
SLN124	TMPS6	Suspended	Beta-thalassemia, myelodysplastic syndrome	Silence therapeutics
QPI-1007	Caspase 2	Suspended	Nonarteritic anterior ischemic optic neuropathy (III), acute primary angle closure glaucoma (II)	Quark Pharmaceuticals
TKM-ApoB (PRO-040201)	ApoB	Suspended	Hypercholesterolemia	Arbutus Biopharma Corporation

(Continued)

Table 2 (Continued).

Drug Name	Target(s)	Current Status	Indication(s)	Company
ALN-RSV01 (Asvasiran sodium)	RSV nucleocapsid "N" gene	Discontinued	Respiratory syncytial virus infections	Alnylam Pharmaceuticals
ARC-520	Conserved regions of HBV	Discontinued	Hepatitis B	Arrowhead Pharmaceuticals
ARC-521	cccDNA and integrated DNA regions of HBV	Discontinued	Hepatitis B	Arrowhead Pharmaceuticals
Revusiran (ALN-TTRsc, SAR438714)	TTR	Discontinued	Transthyretin (TTR)-mediated amyloidosis	Alnylam Pharmaceuticals
ALN-TTRO1	TTR	Discontinued	Transthyretin (TTR)-mediated amyloidosis	Alnylam Pharmaceuticals
CALAA-01	RRM2	Discontinued	Cancer, solid tumor	Calando Pharmaceuticals
Excellair (ACU-XSP-001)	SYK	Discontinued	Asthma	ZaBeCor Pharmaceuticals
DCR-PHI	HAO1	Discontinued	Primary hyperoxaluria type 1	Dicerna Pharmaceuticals, Inc.
ALN-PCS02	PCSK9	Discontinued	Elevated LDL-cholesterol (LDL-C)	Alnylam Pharmaceuticals
DCR-MYC (DCR-M1711)	MYC	Discontinued	Solid tumors, hepatocellular carcinoma, multiple myeloma, non-hodgkin's lymphoma, pancreatic neuroendocrine tumors	Dicerna Pharmaceuticals, Inc.
ARC-AAT	AAT	Discontinued	Alpha-1 antitrypsin deficiency	Arrowhead Pharmaceuticals
ALN-AAT	AAT	Discontinued	Antitrypsin deficiency liver disease	Alnylam Pharmaceuticals
SV40 vectors carrying siRNA	Bcr-Abl	Unknown	Chronic myeloid leukemia (CML)	Hadassah Medical Organization
Bcr-Abl siRNA	Bcr-Abl	Unknown	Chronic myeloid leukemia (CML)	University of Duisburg-Essen
shRNA	XPO1	Unknown	Chronic lymphocytic leukemia (CLL)	Peking University People's Hospital

Note: The information originated from Weng's study¹³ and we updated the current phase status of these drugs in clinical trials.

A **B**

Figure 1 Clinical progression of miRNA drug and siRNA drug. (A) The number of miRNA drugs and siRNA drugs in different clinical periods (terminated/suspended, phase I, phase II, phase III, approved). (B) The ratio of miRNA drugs and siRNA drugs of different clinical periods.

To further explore the cause for the delayed development of current miRNA therapeutics compared to siRNA drugs, we attempted to examine how many targets were not approved when these miRNA drugs entered into the tested subjects. Therefore, we collected all FDA-approved drugs (targeting human genes/proteins) from 1939 to 2019.^{3,4,16–19} Figure 3A showed all ten miRNA drugs had tens and hundreds of unapproved targets, far beyond the siRNA drug. So, how many targets does a recognized drug have? We next profiled the target number of approved

drugs (Figure 3B), and found the number of drug targets was no more than five. SiRNA drugs fell within the range, but miRNA drugs did not.

Analyses for Two Discontinued miRNA Therapeutics-based Projects

To further verify this finding, we collected and analyzed two available miRNA clinical projects that suffered

Figure 2 Flexible complementary ratio between miRNA with target sequence led to TMTME. **(A)** Complementary ratios of miRNA and siRNA with target. **(B)** Target number of miRNA drug* (all containing high-throughput results), miRNA drug (validated) and siRNA drug.

Figure 3 Target number of siRNA drugs obeyed the regular of all approved drug target number. **(A)** Unapproved targets of miRNA drug*, miRNA drug and siRNA drug. **(B)** Target number of miRNA drug*, miRNA drug, siRNA drug and approved drugs.

discontinuation caused by adverse events. According to the ClinicalTrials.gov database¹⁰ (NCT01829971) recorded, MRX34 (a miR-34a mimic) in a phase I clinical trial led to tested objects undergoing five serious immune-related adverse events, therefore terminating the project. Using KOBAS (a web server for annotation and identification of enriched pathways and diseases),²⁰ we enriched 139 experiment-validated target genes of miR-34a in pathway analysis, and selected the top ten pathways, see Figure 4A according to the ranking of enrichment score and Figure 4B according to the ranking of number of genes. It showed that two immune-related pathways (cytokine signaling in the immune system and immune system) were on the list, and some related pathways like signaling by interleukins were also included. We further found that there were 15 approved genes and 25 unapproved genes in the immune

system pathway and 13 approved genes and 16 unapproved genes in cytokine signaling in the immune system pathway (Figure 4C). Based on these facts, it is not hard to understand the emergence of five serious immune-related adverse events in phase I. According to the literature¹² and the Regulus Therapeutics Inc. company report,¹⁴ RG-101, an anti-miR-122 drug, succeeded in phase I but was discontinued in phase II for the occurrence of a few cases of hyperbilirubinemia. We next enriched 71 experiment-validated target genes of miR-122 in disease analysis by KOBAS web server. However, no hyperbilirubinemia-related diseases were among the listed top 10 (Figure 4D and E). And hepatocellular carcinoma (HCC) was enriched as it has been reported that miR-122, a most frequent miRNA in the adult liver,²¹ played a crucial role in HCC in a series of literature,^{6,22,23} indicating the correctness of

Figure 4 Analyses of discontinuation of two miRNA-based clinical projects. **(A and B)** Enrichment for targets of MRX34 in terms of enrichment score and number of genes. **(C)** Unapproved and approved targets number of MRX34 validated targets in the immune system and cytokine signaling in the immune system. **(D and E)** Enrichment for targets of miR-122 (drug RG-101) in terms of enrichment score and number of genes.

the enrichment. Given its emergence in phase II not in phase I, we filtrated 71 target genes in the literature and the KEGG database,²⁴ and got seven hyperbilirubinemia or jaundice (hyperbilirubinemia-related disease) related genes (Figure 5). Only seven related genes were found, and it revealed why hyperbilirubinemia did not occur in most tested objects in phase I but appeared in a few cases in phase II.

Future Directions and Conclusions

TMTME is a typical and inevitable property of miRNA molecules, which is caused by incomplete complementation with the target sequence. TMTME leads to that miRNA could bind to various sequences suitable for the interaction (including protein-coding genes, lncRNA,²⁵ circRNA,²⁶ etc), which is different from all approved drugs (including siRNA drugs) with only a few targets. Emerging siRNA-based products, patisiran and givosiran

approved by the FDA, have been in clinical application, however, miRNA therapeutics was still in its early clinical stage. Therefore, both introduction and removal of miRNA in humans can lead to changes of a wide series of pathways and some of them are unknown, even unpredictable, probably triggering disorders of physiological function or the occurrence of additional disease.

Targeted drug delivery is a pattern of delivering drugs to specific lesion sites of a patient, largely based on nanomedicine, which can enhance solubility and efficacy of drugs and avoid needless interaction with healthy tissues.^{27,28} Targeted drug delivery systems can be designed by recognition of a specific feature in lesion sites.²⁹ In cancers, the antigens and receptors on cell membranes are considered suitable targets of recognition sites for design of these nanoparticles.²⁹ Therefore, targeted drug delivery systems may eliminate or weaken the existing obstacles that were caused by TMTME.

Figure 5 Discontinuation of RG-101 is caused by its hyperbilirubinemia or jaundice-related targets. The hyperbilirubinemia or jaundice-related target genes of miR-122 are identified by literature searching and KEGG enrichment.

Delivering miRNA drugs to pathogenic sites may efficiently avoid excessive toxicity and side effects. However, the defects of the system are high cost, hard to make productivity for delivering nucleotides, and the increased difficulty for adjusting the dosages.^{28,30} Moreover, due to instability of unprotected miRNAs, delivering miRNAs required chemical modifications to avoid rapid degradation in serum, which may impair specificity of miRNAs and lead to off-target effects.³¹ Besides, par-enteral or local injection is the primary approach for delivering miRNA drugs,³² which reduces the amount of miRNA that is transported to the target tissue. Another challenge is that exogenous artificial miRNAs will trigger competition and saturation effect, a competition among exogenous and the endogenous miRNAs for the intracellular machinery, and thus affecting unexpected gene expression and leading to untoward side effects.^{33–35}

Conclusively, in this study, we analyzed the key cause that leads to the slow development of miRNA therapeutics in a drug target perspective and attributed it to TMTME.

Resources, Databases and Servers

We use ClinicalTrials.gov database¹⁰ for obtaining available information of clinical trials, a series of literature^{36–89} for obtaining information for complementary ratio of miRNA with target gene, a study⁹⁰ for getting all siRNA

sequences with target genes, NCBI gene and NCBI blast database for calculating complementary ratio of siRNA with mRNA, KOBAS²⁰ web server for enriching pathways and diseases for adverse events' condition of miRNA therapeutics, KEGG database²⁴ for obtaining hyperbilirubinemia or jaundice-related genes and pathways.

Acknowledgments

This work is supported by the National Natural Science Foundation of China (81902346) and Natural Science Foundation of Jiangxi Province (20192BAB215038).

Disclosure

The authors report no conflicts of interest in this work.

References

1. Lee RC, Feinbaum RL, Ambros V. The *C. elegans* heterochronic gene *lin-4* encodes small RNAs with antisense complementarity to *lin-14*. *Cell*. 1993;75:843–854. doi:10.1016/0092-8674(93)90529-y
2. Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. *Nature*. 2001;411:494–498. doi:10.1038/35078107
3. Mullard A. 2018 FDA drug approvals. *Nat Rev Drug Discov*. 2019;18:85–89. doi:10.1038/d41573-019-00014-x
4. Mullard A. 2019 FDA drug approvals. *Nat Rev Drug Discov*. 2020;19:79–84. doi:10.1038/d41573-020-00001-7
5. Li Z, Rana TM. Therapeutic targeting of microRNAs: current status and future challenges. *Nat Rev Drug Discov*. 2014;13:622–638. doi:10.1038/nrd4359

6. Bandiera S, Pfeffer S, Baumert TF, Zeisel MB. miR-122—a key factor and therapeutic target in liver disease. *J Hepatol*. 2015;62:448–457. doi:10.1016/j.jhep.2014.10.004
7. Bertoli G, Cava C, Castiglioni I. MicroRNAs: new biomarkers for diagnosis, prognosis, therapy prediction and therapeutic tools for breast cancer. *Theranostics*. 2015;5:1122–1143. doi:10.7150/thno.11543
8. Ganju A, Khan S, Hafeez BB, et al. miRNA nanotherapeutics for cancer. *Drug Discov Today*. 2017;22:424–432. doi:10.1016/j.drudis.2016.10.014
9. Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. *Nat Rev Drug Discov*. 2017;16:203–222. doi:10.1038/nrd.2016.246
10. Zarin DA, Tse T, Williams RJ, Califf RM, Ide NC. The ClinicalTrials.gov results database—update and key issues. *N Engl J Med*. 2011;364:852–860. doi:10.1056/NEJMsa1012065
11. Jing HZ, Qiu F, Chen SZ, Su L, Qu C. [Tripartite-motif protein 25 and pyruvate kinase M2 protein expression in non-small cell lung cancer]. *Nan Fang Yi Ke Da Xue Xue Bao*. 2015;35:437–441. Chinese.
12. van der Ree MH, de Vree JM, Stelma F, et al. Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial. *Lancet*. 2017;389:709–717. doi:10.1016/S0140-6736(16)31715-9
13. Weng Y, Xiao H, Zhang J, Liang XJ, Huang Y. RNAi therapeutic and its innovative biotechnological evolution. *Biotechnol Adv*. 2019;37:801–825. doi:10.1016/j.biotechadv.2019.04.012
14. Tao JL, Luo M, Sun H, et al. Overexpression of tripartite motif containing 26 inhibits non-small cell lung cancer cell growth by suppressing PI3K/AKT signaling. *Kaohsiung J Med Sci*. 2020;36:417–422. doi:10.1002/kjm2.12194
15. Huang HY, Lin Y-C-D, Li J, et al. miRTarBase 2020: updates to the experimentally validated microRNA-target interaction database. *Nucleic Acids Res*. 2020;48:D148–D154. doi:10.1093/nar/gkz896
16. Mullard A. 2015 FDA drug approvals. *Nat Rev Drug Discov*. 2016;15:73–76. doi:10.1038/nrd.2016.15
17. Santos R, Ursu O, Gaulton A, et al. A comprehensive map of molecular drug targets. *Nat Rev Drug Discov*. 2017;16:19–34. doi:10.1038/nrd.2016.230
18. Mullard A. 2016 FDA drug approvals. *Nat Rev Drug Discov*. 2017;16:73–76. doi:10.1038/nrd.2017.14
19. Mullard A. 2017 FDA drug approvals. *Nat Rev Drug Discov*. 2018;17:81–85. doi:10.1038/nrd.2018.4
20. Xie C, Mao X, Huang J, et al. KOBAS 2.0: a web server for annotation and identification of enriched pathways and diseases. *Nucleic Acids Res*. 2011;39:W316–W322. doi:10.1093/nar/gkr483
21. Girard M, Jacquemin E, Munnich A, Lyonnet S, Henrion-Caude A. miR-122, a paradigm for the role of microRNAs in the liver. *J Hepatol*. 2008;48:648–656. doi:10.1016/j.jhep.2008.01.019
22. Wang D, Sun X, Wei Y, et al. Nuclear miR-122 directly regulates the biogenesis of cell survival oncomiR miR-21 at the posttranscriptional level. *Nucleic Acids Res*. 2018;46:2012–2029. doi:10.1093/nar/gkx1254
23. Turato C, Fornari F, Pollutri D, et al. MiR-122 targets SerpinB3 and is involved in sorafenib resistance in hepatocellular carcinoma. *J Clin Med*. 2019;8:171. doi:10.3390/jcm8020171
24. Kanehisa M, Sato Y. KEGG Mapper for inferring cellular functions from protein sequences. *Protein Sci*. 2020;29:28–35. doi:10.1002/pro.3711
25. Cesana M, Cacchiarelli D, Legnini I, et al. A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. *Cell*. 2011;147:358–369. doi:10.1016/j.cell.2011.09.028
26. Hansen TB, Jensen TI, Clausen BH, et al. Natural RNA circles function as efficient microRNA sponges. *Nature*. 2013;495:384–388. doi:10.1038/nature11993
27. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. *Nat Rev Drug Discov*. 2008;7:771–782. doi:10.1038/nrd2614
28. Muller RH, Keck CM. Challenges and solutions for the delivery of biotech drugs—a review of drug nanocrystal technology and lipid nanoparticles. *J Biotechnol*. 2004;113:151–170. doi:10.1016/j.jbiotec.2004.06.007
29. Guan S, Zhang Q, Bao J, Hu R, Czech T, Tang J. Recognition sites for cancer-targeting drug delivery systems. *Curr Drug Metab*. 2019;20:815–834. doi:10.2174/1389200220666191003161114
30. Zhao H, Yuan X, Yu J, et al. Magnesium-stabilized multifunctional DNA nanoparticles for tumor-targeted and pH-responsive drug delivery. *ACS Appl Mater Interfaces*. 2018;10:15418–15427. doi:10.1021/acsami.8b01932
31. Corey DR. Chemical modification: the key to clinical application of RNA interference? *J Clin Invest*. 2007;117:3615–3622. doi:10.1172/JCI33483
32. Forbes DC, Peppas NA. Oral delivery of small RNA and DNA. *J Control Release*. 2012;162:438–445. doi:10.1016/j.jconrel.2012.06.037
33. Grimm D, Streetz KL, Jopling CL, et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. *Nature*. 2006;441:537–541. doi:10.1038/nature04791
34. Khan AA, Betel D, Miller ML, et al. Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs. *Nat Biotechnol*. 2009;27:549–555. doi:10.1038/nbt.1543
35. Zhang Y, Wang Z, Gemeinhart RA. Progress in microRNA delivery. *J Control Release*. 2013;172:962–974. doi:10.1016/j.jconrel.2013.09.015
36. Labbaye C, Spinello I, Quaranta MT, et al. A three-step pathway comprising PLZF/miR-146a/CXCR4 controls megakaryopoiesis. *Nat Cell Biol*. 2008;10:788–801. doi:10.1038/ncb1741
37. Pan W, Zhu S, Yuan M, et al. MicroRNA-21 and microRNA-148a contribute to DNA hypomethylation in lupus CD4 + T cells by directly and indirectly targeting DNA methyltransferase 1. *J Immunol*. 2010;184:6773–6781. doi:10.4049/jimmunol.0904060
38. Reddy SD, Pakala SB, Ohshiro K, Rayala SK, Kumar R. MicroRNA-661, a c/EBPalpha target, inhibits metastatic tumor antigen 1 and regulates its functions. *Cancer Res*. 2009;69:5639–5642. doi:10.1158/0008-5472.CAN-09-0898
39. Zhang J, Zhou Y, Ma L, et al. The alteration of miR-222 and its target genes in nickel-induced tumor. *Biol Trace Elem Res*. 2013;152:267–274. doi:10.1007/s12011-013-9619-6
40. Sun C, Li NA, Zhou BO, et al. miR-222 is upregulated in epithelial ovarian cancer and promotes cell proliferation by downregulating P27(kip1). *Oncol Lett*. 2013;6:507–512. doi:10.3892/ol.2013.1393
41. Liu X, Yu J, Jiang L, et al. MicroRNA-222 regulates cell invasion by targeting matrix metalloproteinase 1 (MMP1) and manganese superoxide dismutase 2 (SOD2) in tongue squamous cell carcinoma cell lines. *Cancer Genomics Proteomics*. 2009;6:131–139.
42. Fornari F, Gramantieri L, Ferracin M, et al. MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. *Oncogene*. 2008;27:5651–5661. doi:10.1038/onc.2008.178
43. Ye Z, Hao R, Cai Y, Wang X, Huang G. Knockdown of miR-221 promotes the cisplatin-inducing apoptosis by targeting the BIM-Bax/Bak axis in breast cancer. *Tumour Biol*. 2016;37:4509–4515. doi:10.1007/s13277-015-4267-4
44. Gramantieri L, Fornari F, Ferracin M, et al. MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. *Clin Cancer Res*. 2009;15:5073–5081. doi:10.1158/1078-0432.CCR-09-0092
45. Yang T, Zhang G-F, Chen X-F, et al. MicroRNA-214 provokes cardiac hypertrophy via repression of EZH2. *Biochem Biophys Res Commun*. 2013;436:578–584. doi:10.1016/j.bbrc.2013.05.079

46. Wang P, Zou F, Zhang X, et al. microRNA-21 negatively regulates Cdc25A and cell cycle progression in colon cancer cells. *Cancer Res.* 2009;69:8157–8165. doi:10.1158/0008-5472.CAN-09-1996
47. Fu YR, Liu X-J, Li X-J, et al. MicroRNA miR-21 attenuates human cytomegalovirus replication in neural cells by targeting Cdc25a. *J Virol.* 2015;89:1070–1082. doi:10.1128/JVI.01740-14
48. Zhang S, Wan Y, Pan T, et al. MicroRNA-21 inhibitor sensitizes human glioblastoma U251 stem cells to chemotherapeutic drug temozolomide. *J Mol Neurosci.* 2012;47:346–356. doi:10.1007/s12031-012-9759-8
49. Asangani IA, Rasheed SAK, Nikolova DA, et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pcdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. *Oncogene.* 2008;27:2128–2136. doi:10.1038/sj.onc.1210856
50. Hiyoshi Y, Kamohara H, Karashima R, et al. MicroRNA-21 regulates the proliferation and invasion in esophageal squamous cell carcinoma. *Clin Cancer Res.* 2009;15:1915–1922. doi:10.1158/1078-0432.CCR-08-2545
51. Li S, Fu H, Wang Y, et al. MicroRNA-101 regulates expression of the v-fos FBJ murine osteosarcoma viral oncogene homolog (FOS) oncogene in human hepatocellular carcinoma. *Hepatology.* 2009;49:1194–1202. doi:10.1002/hep.22757
52. Luo W, Li G, Yi Z, Nie Q, Zhang X. E2F1-miR-20a-5p/20b-5p auto-regulatory feedback loop involved in myoblast proliferation and differentiation. *Sci Rep.* 2016;6:27904. doi:10.1038/srep27904
53. Ryan J, Tivnan A, Fay J, et al. MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome. *Br J Cancer.* 2012;107:967–976. doi:10.1038/bjc.2012.356
54. Luan W, Qian Y, Ni X, et al. miR-204-5p acts as a tumor suppressor by targeting matrix metalloproteinases-9 and B-cell lymphoma-2 in malignant melanoma. *Onco Targets Ther.* 2017;10:1237–1246. doi:10.2147/OTT.S128819
55. Cochrane DR, Spoelstra NS, Howe EN, Nordeen SK, Richer JK. MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. *Mol Cancer Ther.* 2009;8:1055–1066. doi:10.1158/1535-7163.MCT-08-1046
56. Zhang QQ, Xu H, Huang M-B, et al. MicroRNA-195 plays a tumor-suppressor role in human glioblastoma cells by targeting signaling pathways involved in cellular proliferation and invasion. *Neuro Oncol.* 2012;14:278–287. doi:10.1093/neuonc/nor216
57. Jia LF, Wei SB, Gong K, Gan YH, Yu GY, Kim AL. Prognostic implications of microRNA miR-195 expression in human tongue squamous cell carcinoma. *PLoS One.* 2013;8:e56634. doi:10.1371/journal.pone.0056634
58. Luo Q, Wei C, Li X, et al. MicroRNA-195-5p is a potential diagnostic and therapeutic target for breast cancer. *Oncol Rep.* 2014;31:1096–1102. doi:10.3892/or.2014.2971
59. Han K, Chen X, Bian N, et al. MicroRNA profiling identifies MiR-195 suppresses osteosarcoma cell metastasis by targeting CCND1. *Oncotarget.* 2015;6:8875–8889. doi:10.18632/oncotarget.3560
60. Ji J, Yamashita T, Budhu A, et al. Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. *Hepatology.* 2009;50:472–480. doi:10.1002/hep.22989
61. Zhang XJ, Ye H, Zeng CW, et al. Dysregulation of miR-15a and miR-214 in human pancreatic cancer. *J Hematol Oncol.* 2010;3:46. doi:10.1186/1756-8722-3-46
62. Pogue AI, Li YY, Cui J-G, et al. Characterization of an NF-kappaB-regulated, miRNA-146a-mediated down-regulation of complement factor H (CFH) in metal-sulfate-stressed human brain cells. *J Inorg Biochem.* 2009;103:1591–1595. doi:10.1016/j.jinorgbio.2009.05.012
63. Xu Z, Zeng X, Xu J, et al. Isorhapontigenin suppresses growth of patient-derived glioblastoma spheres through regulating miR-145/SOX2/cyclin D1 axis. *Neuro Oncol.* 2016;18:830–839. doi:10.1093/neuonc/nov298
64. Minami K, Taniguchi K, Sugito N, et al. MiR-145 negatively regulates Warburg effect by silencing KLF4 and PTBP1 in bladder cancer cells. *Oncotarget.* 2017;8:33064–33077. doi:10.18632/oncotarget.16524
65. Hu M, Xia M, Chen X, et al. MicroRNA-141 regulates Smad interacting protein 1 (SIP1) and inhibits migration and invasion of colorectal cancer cells. *Dig Dis Sci.* 2010;55:2365–2372. doi:10.1007/s10620-009-1008-9
66. Liu LY, Wang W, Zhao LY, et al. Mir-126 inhibits growth of SGC-7901 cells by synergistically targeting the oncogenes PI3KR2 and Crk, and the tumor suppressor PLK2. *Int J Oncol.* 2014;45:1257–1265. doi:10.3892/ijo.2014.2516
67. Bai S, Nasser MW, Wang B, et al. MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. *J Biol Chem.* 2009;284:32015–32027. doi:10.1074/jbc.M109.016774
68. Sampath D, Calin GA, Puduvali VK, et al. Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation. *Blood.* 2009;113:3744–3753. doi:10.1182/blood-2008-09-178707
69. Luo ZL, Luo H-J, Fang C, et al. Negative correlation of ITCH E3 ubiquitin ligase and miRNA-106b dictates metastatic progression in pancreatic cancer. *Oncotarget.* 2016;7:1477–1485. doi:10.18632/oncotarget.6395
70. Varambally S, Cao Q, Mani R-S, et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. *Science.* 2008;322:1695–1699. doi:10.1126/science.1165395
71. Alajez NM, Shi W, Hui ABY, et al. Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98. *Cell Death Dis.* 2010;1:e85. doi:10.1038/cddis.2010.64
72. Chen DL, Ju H-Q, Lu Y-X, et al. Long non-coding RNA XIST regulates gastric cancer progression by acting as a molecular sponge of miR-101 to modulate EZH2 expression. *J Exp Clin Cancer Res.* 2016;35:142. doi:10.1186/s13046-016-0420-1
73. Liu J, Lu K-H, Liu Z-L, et al. MicroRNA-100 is a potential molecular marker of non-small cell lung cancer and functions as a tumor suppressor by targeting polo-like kinase 1. *BMC Cancer.* 2012;12:519. doi:10.1186/1471-2407-12-519
74. Nasser MW, Datta J, Nuovo G, et al. Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. *J Biol Chem.* 2008;283:33394–33405. doi:10.1074/jbc.M804788200
75. Zhu X, Wu L, Yao J, et al. MicroRNA let-7c inhibits cell proliferation and induces cell cycle arrest by targeting CDC25A in human hepatocellular carcinoma. *PLoS One.* 2015;10:e0124266. doi:10.1371/journal.pone.0124266
76. Ye Z, Shen N, Weng Y, et al. Low miR-145 silenced by DNA methylation promotes NSCLC cell proliferation, migration and invasion by targeting mucin 1. *Cancer Biol Ther.* 2015;16:1071–1079. doi:10.1080/15384047.2015.1046024
77. Vilardo E, Barbato C, Ciotti M, Cogoni C, Ruberti F. MicroRNA-101 regulates amyloid precursor protein expression in hippocampal neurons. *J Biol Chem.* 2010;285:18344–18351. doi:10.1074/jbc.M110.112664
78. Garzon R, Liu S, Fabbri M, et al. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. *Blood.* 2009;113:6411–6418. doi:10.1182/blood-2008-07-170589
79. Zhang X, Zhu W, Zhang J, et al. MicroRNA-650 targets ING4 to promote gastric cancer tumorigenicity. *Biochem Biophys Res Commun.* 2010;395:275–280. doi:10.1016/j.bbrc.2010.04.005

80. Zhang J, Zhao H, Chen J, et al. Interferon-beta-induced miR-155 inhibits osteoclast differentiation by targeting SOCS1 and MITF. *FEBS Lett.* **2012**;586:3255–3262. doi:10.1016/j.febslet.2012.06.047
81. Lei K, Du W, Lin S, et al. 3B, a novel photosensitizer, inhibits glycolysis and inflammation via miR-155-5p and breaks the JAK/STAT3/SOCS1 feedback loop in human breast cancer cells. *Biomed Pharmacother.* **2016**;82:141–150. doi:10.1016/j.biopha.2016.04.049
82. Pathak S, Grillo AR, Scarpa M, et al. MiR-155 modulates the inflammatory phenotype of intestinal myofibroblasts by targeting SOCS1 in ulcerative colitis. *Exp Mol Med.* **2015**;47:e164. doi:10.1038/emmm.2015.21
83. Ji J, Zhao L, Budhu A, et al. Let-7g targets collagen type I alpha2 and inhibits cell migration in hepatocellular carcinoma. *J Hepatol.* **2010**;52:690–697. doi:10.1016/j.jhep.2009.12.025
84. Majid S, Dar AA, Saini S, et al. Regulation of minichromosome maintenance gene family by microRNA-1296 and genistein in prostate cancer. *Cancer Res.* **2010**;70:2809–2818. doi:10.1158/0008-5472.CAN-09-4176
85. Chen J, Feilotter HE, Paré GC, et al. MicroRNA-193b represses cell proliferation and regulates cyclin D1 in melanoma. *Am J Pathol.* **2010**;176:2520–2529. doi:10.2353/ajpath.2010.091061
86. Tie J, Pan Y, Zhao L, et al. MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor. *PLoS Genet.* **2010**;6:e1000879. doi:10.1371/journal.pgen.1000879
87. Doebele C, Bonauer A, Fischer A, et al. Members of the microRNA-17-92 cluster exhibit a cell-intrinsic antiangiogenic function in endothelial cells. *Blood.* **2010**;115:4944–4950. doi:10.1182/blood-2010-01-264812
88. Jiang L, Liu X, Kolokythas A, et al. Downregulation of the Rho GTPase signaling pathway is involved in the microRNA-138-mediated inhibition of cell migration and invasion in tongue squamous cell carcinoma. *Int J Cancer.* **2010**;127:505–512. doi:10.1002/ijc.25320
89. Jin Y, Chen Z, Liu X, Zhou X. Evaluating the microRNA targeting sites by luciferase reporter gene assay. *Methods Mol Biol.* **2013**;936:117–127. doi:10.1007/978-1-62703-083-0_10
90. Konieczkowski DJ, Garraway LA. Resistance to EGFR blockade in colorectal cancer: liquid biopsies and latent subclones. *Cell Res.* **2013**;23:13–14. doi:10.1038/cr.2012.115

Drug Design, Development and Therapy

Dovepress

Publish your work in this journal

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are a feature of the journal, which has also

been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/drug-design-development-and-therapy-journal>